Page 3 - Fred Schwarzer News Today

Operator: Good day, everyone, and welcome to the IGM Biosciences Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Todays call is being recorded.

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $25.33, but opened at $25.99. IGM Biosciences shares last traded at $24.67, with a volume of 58 shares changing hands. Wall Street Analyst Weigh In A number of equities research analysts have […]

– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects –MOUNTAIN VIEW, Calif., Jan. 17, 2023 -- IGM Biosciences, Inc. , a clinical-stage... | January 17, 2023

IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Data from T cell Engager Portfolio for Hematologic Malignancies, Including First... | November 3, 2022

GuruFocus Article or News written by PurpleRose and the topic is about:

– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing...

Collaboration will involve the development of new class IgM antibodies with a view to gaining market approval - News - PharmaTimes

Sanofi (NASDAQ: SNY) and IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious...